Epistem has entered into a three-year collaboration with Sanofi-aventis U.S., Inc. for the use of Epistem’s biomarker gene expression profiling and immunohistochemistry technologies. Epistem will provide discovery through to clinical biomarker support for Sanofi’s oncology programs. Epistem may receive as much as $4 million in research support payments including certain cost reimbursement. The collaboration is expected to establish a biomarker strategy aimed at identifying biological response...